Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of giredestrant in grade 1 endometrial cancer
2022-002443-21Phase 2Active
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of giredestrant in endometrial cancer (EC), sponsored by Roche. Primary endpoint: Regression rate by Month 6. Started Nov 2022; status: active.
02
Drugs
giredestrant
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2022-002443-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002443-21.